Why the study?
Does interventional ASD closure using the Occlutech Figulla ASD device series provide safe and effective closure in patients with secundum atrial septal defects?
Does interventional ASD closure using the Occlutech Figulla ASD device series provide safe and effective closure in patients with secundum atrial septal defects?
The Occlutech Figulla ASD device series provides a highly successful and safe option for secundum ASD closure across a wide range of defect morphologies, with no reported aortic erosions.
Answers are grounded in this paper and cite their sources.
Registry data support device feasibility across ages; leaves open randomized comparisons before practice change.
BACKGROUND: The Occlutech Figulla ASD device series (OFSO) shows an improved device design for interventional ASD closure, larger follow-up series are missing. METHODS: We retrospectively reviewed the feasibility, safety, implantation properties, results, and follow-up of ASD closure using Occlutech devices over a 5 year period by establishing a multi-institutional collaborative result registry with 16 contributing centers from 11 countries (IRFACODE). RESULTS: In 1315 patients of all age groups (female 66.9%), successful (98%) ASD closure was performed (mean age 28.9 years, weight 52 kg, height 148.6 cm). Of the defects, 47.9% showed no or only a deficient aortic rim; in 11.9%, there was more than one defect; a septum aneurysm was present in 21.5%; and the mean implanted device size was 20.5 mm. Immediate closure was achieved in 78.6%, at discharge in 83.1%, and 96.4% and 97.3% at 6 and 12 months follow-up, respectively. During a mean follow-up of 2.7 years (in total 3597 patient years), significant complications were minimal (total = 8, <1%) with secondary device embolizations in five and AV-blocks in three patients. No erosion or death was reported. CONCLUSION: ASD closure using OFSO is feasible in a large variety of patients, safe with only a minimal risk of severe side effects and especially without any aortic erosions despite a large percentage of large and complicated defects.
No takes yet. Share an insight, caveat, or question.
Haas et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: